If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to ...

WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

5-Fluorouracil 4% cream achieved total clearance in 54.5% and partial clearance in 24.2% of hyperkeratotic actinic keratosis (AK) lesions at 3 months, demonstrating a good safety profile with high ...